IL128564A0 - Lentiviral vectors - Google Patents
Lentiviral vectorsInfo
- Publication number
- IL128564A0 IL128564A0 IL12856497A IL12856497A IL128564A0 IL 128564 A0 IL128564 A0 IL 128564A0 IL 12856497 A IL12856497 A IL 12856497A IL 12856497 A IL12856497 A IL 12856497A IL 128564 A0 IL128564 A0 IL 128564A0
- Authority
- IL
- Israel
- Prior art keywords
- lentiviral vectors
- vector particles
- provirus
- letiviruses
- ltr
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 3
- 239000002245 particle Substances 0.000 abstract 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 1
- 230000001177 retroviral effect Effects 0.000 abstract 1
- 230000002463 transducing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Mushroom Cultivation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9621680.9A GB9621680D0 (en) | 1996-10-17 | 1996-10-17 | Lentiviral vectors |
| PCT/GB1997/002858 WO1998017816A1 (en) | 1996-10-17 | 1997-10-17 | Lentiviral vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL128564A0 true IL128564A0 (en) | 2000-01-31 |
Family
ID=10801598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12856497A IL128564A0 (en) | 1996-10-17 | 1997-10-17 | Lentiviral vectors |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6235522B1 (xx) |
| EP (1) | EP0939827B1 (xx) |
| JP (1) | JP2001502903A (xx) |
| KR (1) | KR20000049250A (xx) |
| CN (1) | CN1195864C (xx) |
| AT (1) | ATE520783T1 (xx) |
| AU (1) | AU737801B2 (xx) |
| BG (1) | BG103334A (xx) |
| CA (1) | CA2268271A1 (xx) |
| CZ (1) | CZ137299A3 (xx) |
| GB (2) | GB9621680D0 (xx) |
| HU (1) | HUP0000442A3 (xx) |
| IL (1) | IL128564A0 (xx) |
| NO (1) | NO991742D0 (xx) |
| NZ (1) | NZ334522A (xx) |
| PL (1) | PL332876A1 (xx) |
| WO (1) | WO1998017816A1 (xx) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6924123B2 (en) * | 1996-10-29 | 2005-08-02 | Oxford Biomedica (Uk) Limited | Lentiviral LTR-deleted vector |
| CN1247788C (zh) | 1997-05-13 | 2006-03-29 | 北卡罗来纳-查佩尔山大学 | 基于慢病毒的基因转移载体 |
| FI112580B (fi) | 1997-06-27 | 2003-12-15 | Nokia Corp | Kutsunsiirron reititys peruspalvelukohtaisesti |
| ATE298371T1 (de) | 1997-09-24 | 2005-07-15 | Univ California | Nicht-primaten lentivirale vektoren und verpackungssysteme |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| EP1088086A4 (en) | 1998-06-24 | 2003-01-08 | Musc Found For Res Dev | TISSUE-SPECIFIC AND TARGET RNA-SPECIFIC RIBOZYMS |
| US6958226B1 (en) | 1998-09-11 | 2005-10-25 | The Children's Medical Center Corp. | Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins |
| JP2002541822A (ja) | 1999-04-14 | 2002-12-10 | エム ユー エス シー ファンデーション フォー リサーチ ディベロップメント | 組織特異的および病原体特異的毒性物質ならびにリボザイム |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| ATE368122T1 (de) | 1999-04-29 | 2007-08-15 | Cell Genesys Inc | Verfahren und mittel für die herstellung von sicheren rekombinanten lentiviralen vektoren mit hohem titer |
| EP1083230A1 (en) * | 1999-09-10 | 2001-03-14 | Academisch Medisch Centrum Amsterdam | Viral replicons and viruses dependent on inducing agents |
| CA2388301C (en) | 1999-10-22 | 2011-01-04 | Aventis Pasteur Limited | Modified gp100 and uses thereof |
| US6656706B2 (en) | 1999-12-23 | 2003-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes |
| EP1702983A3 (en) | 2000-04-13 | 2007-01-10 | Medical University of South Carolina | Tissue-specific and pathogen-specific toxic agents, ribozymes, DNAzymes and antisense oligonucleotides and methods of use thereof |
| US7851212B2 (en) | 2000-05-10 | 2010-12-14 | Sanofi Pasteur Limited | Immunogenic polypeptides encoded by MAGE minigenes and uses thereof |
| US7101541B2 (en) | 2000-05-19 | 2006-09-05 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Utilization of non-viral sequences for minus-strand DNA transfer and gene reconstitution |
| CA2426647A1 (en) * | 2000-10-20 | 2002-05-02 | Whitehead Institute For Biomedical Research | Expression vectors and uses thereof |
| US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
| US6712612B1 (en) | 2000-12-12 | 2004-03-30 | Genecure Llc | Safe and stable retroviral helper cell line and related compositions and methods |
| AU2002307393A1 (en) * | 2001-04-20 | 2002-11-05 | The Salk Institute For Biological Studies | Inducible expression of transfected genes |
| US20030039636A1 (en) * | 2001-05-01 | 2003-02-27 | Genetix Pharmaceuticals, Inc. | Novel self-inactivating (SIN) lentiviral vectors |
| ATE527347T1 (de) | 2001-08-02 | 2011-10-15 | Inst Clayton De La Rech | Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen |
| CA2462628C (en) * | 2001-10-02 | 2019-08-20 | Institut Clayton De La Recherche | Restricted expression lentiviral vectors |
| DK2348119T3 (en) | 2002-02-01 | 2017-08-21 | Oxford Biomedica (Uk) Ltd | Polycistronic lentiviral vector |
| WO2005035773A2 (en) * | 2003-10-08 | 2005-04-21 | Sanofi Pasteur, Inc. | Modified cea /b7 vector |
| ATE369895T1 (de) | 2002-04-09 | 2007-09-15 | Sanofi Pasteur Ltd | Modifizierte cea nucleinsäure und expressionsvektoren |
| KR101002955B1 (ko) * | 2002-04-26 | 2010-12-21 | 인스티튜트 클레이톤 드 라 리쎄르셰 | 개선된 키메라 당단백질 및 슈도타입 렌티바이러스 벡터 |
| CA2506798C (en) * | 2002-11-22 | 2013-01-22 | Institut Clayton De La Recherche | Compositions and systems for the regulation of genes |
| US20070036721A1 (en) * | 2003-09-23 | 2007-02-15 | Uab Resarch Foundation | Methods and compositions for in vivo inflammation monitoring |
| WO2005118809A2 (en) * | 2004-04-29 | 2005-12-15 | The University Of North Carolina At Chapel Hill | Methods and compositions for enhancing cell adhesion properties |
| US20060292159A1 (en) * | 2005-06-08 | 2006-12-28 | Ranscht Barbara E | Methods for the inhibition of neovascularization and cancer metastasis |
| GB201202516D0 (en) | 2012-02-13 | 2012-03-28 | Ucl Business Plc | Materials and methods relating to packaging cell lines |
| WO2013184209A1 (en) | 2012-06-04 | 2013-12-12 | Ludwig Institute For Cancer Research Ltd. | Mif for use in methods of treating subjects with a neurodegenerative disorder |
| KR101554678B1 (ko) | 2012-10-19 | 2015-09-21 | 영남대학교 산학협력단 | 식물 바이러스를 이용한 식물체 형질전환을 위한 유전자 전달 시스템 및 이의 용도 |
| RS61387B2 (sr) | 2013-02-15 | 2024-06-28 | Bioverativ Therapeutics Inc | Gen optimizovanog faktora viii |
| US20160060652A1 (en) * | 2013-03-13 | 2016-03-03 | Lapian's Corp | Microvesicle and method for producing the same |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| EP3031923A1 (en) * | 2014-12-11 | 2016-06-15 | Institut Pasteur | Lentiviral vector-based japanese encephalitis immunogenic composition |
| KR20180118659A (ko) | 2016-02-01 | 2018-10-31 | 바이오버라티브 테라퓨틱스 인크. | 최적화된 viii 인자 유전자 |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| IL326479A (en) | 2016-10-12 | 2026-04-01 | Bioverativ Usa Inc | Anti-c1s antibodies and methods of use thereof |
| EP3535294B1 (en) | 2016-11-07 | 2025-02-12 | Neuracle Science Co., Ltd. | Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof |
| JP7012384B2 (ja) | 2017-06-27 | 2022-02-14 | ニューラクル サイエンス カンパニー リミテッド | 癌治療のための抗ｆａｍ１９ａ５抗体の用途 |
| CN111344011B (zh) | 2017-06-27 | 2024-01-26 | 纽洛可科学有限公司 | 抗fam19a5抗体用于治疗纤维化的用途 |
| CN110972463B (zh) | 2017-06-27 | 2024-05-28 | 纽洛可科学有限公司 | 抗序列相似家族19成员a5抗体在治疗青光眼中的用途 |
| BR112019027729A2 (pt) | 2017-06-27 | 2020-08-18 | Neuracle Science Co., Ltd | anticorpos anti-fam19a5 e seus usos |
| US11597917B2 (en) | 2017-07-06 | 2023-03-07 | The Medical College Of Wisconsin, Inc. | In vitro and in vivo enrichment strategy targeting lymphocytes derived from vector transduced HSCs for therapy of disorders |
| CN111527105B (zh) | 2017-10-11 | 2024-10-25 | 美国比奥维拉迪维股份有限公司 | 诱导补体活性的方法 |
| US20210038744A1 (en) | 2018-02-01 | 2021-02-11 | Bioverativ Therapeutics Inc. | Use of lentiviral vectors expressing factor viii |
| KR102866162B1 (ko) | 2018-04-24 | 2025-10-01 | 주식회사 뉴라클사이언스 | 신경병성 통증의 치료를 위한 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리의 용도 |
| US12239693B2 (en) | 2018-04-27 | 2025-03-04 | The Medical College Of Wisconsin, Inc. | Use of lentivector-transduced T-Rapa cells for amelioration of lysosomal storage disorders |
| KR20240056644A (ko) | 2018-05-10 | 2024-04-30 | 주식회사 뉴라클사이언스 | 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법 |
| MX2020013923A (es) | 2018-06-29 | 2021-03-29 | Apitbio Inc | Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos. |
| KR102648762B1 (ko) | 2018-10-16 | 2024-03-19 | 주식회사 뉴라클사이언스 | 항-fam19a5 항체의 용도 |
| CA3119341A1 (en) | 2018-11-16 | 2020-05-22 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor |
| CA3121786A1 (en) | 2018-12-06 | 2020-06-11 | Bioverativ Therapeutics Inc. | Use of lentiviral vectors expressing factor ix |
| KR20200071198A (ko) | 2018-12-10 | 2020-06-19 | 네오이뮨텍, 인코퍼레이티드 | Nrf2 발현 조절 기반 T 세포 항암면역치료법 |
| US20220144902A1 (en) * | 2018-12-25 | 2022-05-12 | National Center Of Neurology And Psychiatry | Method for inducing muscular cells using cells in spot urine |
| KR20240000655A (ko) | 2018-12-27 | 2024-01-02 | 주식회사 뉴라클사이언스 | 죽상경화증을 치료하기 위한 항-fam19a5 항체의 사용 |
| MX2021004504A (es) | 2019-01-02 | 2021-10-01 | Neuracle Science Co Ltd | Anti-familia con similitud de secuencia 19, anticuerpos del miembro a5 y método de uso de los mismos. |
| US12565643B2 (en) | 2019-09-18 | 2026-03-03 | The Medical College Of Wisconsin, Inc. | Alpha-galactosidase protein for enzyme replacement therapy (ERT) and methods of use |
| JP7803014B2 (ja) | 2019-09-30 | 2026-01-21 | バイオベラティブ セラピューティクス インコーポレイテッド | レンチウイルスベクター製剤 |
| AU2021207586A1 (en) | 2020-01-13 | 2022-07-21 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of IL-7 protein and a bispecific antibody |
| WO2021151006A2 (en) | 2020-01-22 | 2021-07-29 | Outpace Bio, Inc. | Chimeric polypeptides |
| EP4093751A1 (en) | 2020-01-22 | 2022-11-30 | Outpace Bio, Inc. | Chimeric polypeptides |
| AU2021217373A1 (en) | 2020-02-05 | 2022-08-04 | Neoimmunetech, Inc. | Method of treating a solid tumor with a combination of an IL-7 protein and CAR-bearing immune cells |
| JP2023537565A (ja) | 2020-06-24 | 2023-09-04 | バイオベラティブ セラピューティクス インコーポレイテッド | タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第ｖｉｉｉ因子を除去する方法 |
| WO2022087453A1 (en) | 2020-10-22 | 2022-04-28 | Lyell Immunopharma, Inc. | Chimeric activation receptors |
| WO2022093718A1 (en) | 2020-10-26 | 2022-05-05 | Neoimmunetech, Inc. | Methods of inducing stem cell mobilization |
| KR20230104176A (ko) | 2020-11-02 | 2023-07-07 | 네오이뮨텍, 인코퍼레이티드 | 코로나바이러스의 치료를 위한 인터류킨-7의 용도 |
| JP2023549112A (ja) | 2020-11-05 | 2023-11-22 | ネオイミューンテック， インコーポレイテッド | Ｉｌ－７タンパク質とヌクレオチドワクチンの組み合わせで腫瘍を治療する方法 |
| KR20240028362A (ko) | 2021-05-28 | 2024-03-05 | 라이엘 이뮤노파마, 인크. | Nr4a3-결핍 면역 세포 및 이의 용도 |
| KR20240027676A (ko) | 2021-06-02 | 2024-03-04 | 라이엘 이뮤노파마, 인크. | Nr4a3-결핍 면역 세포 및 이의 용도 |
| KR20240067122A (ko) | 2021-09-30 | 2024-05-16 | 바이오버라티브 테라퓨틱스 인크. | 감소된 면역원성을 갖는 인자 viii 폴리펩타이드를 암호화하는 핵산 |
| US20250129067A1 (en) | 2021-11-08 | 2025-04-24 | Progentos Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
| CN119836296A (zh) | 2021-12-30 | 2025-04-15 | 新免疫技术有限公司 | 用il-7蛋白和vegf拮抗剂的组合治疗肿瘤的方法 |
| CA3262766A1 (en) | 2022-07-28 | 2024-02-01 | Stemcell Technologies Canada Inc. | Polynucleotides encoding bound antigens and their uses |
| JP2026504619A (ja) | 2022-11-07 | 2026-02-06 | ネオイミューンテック， インコーポレイテッド | 非メチル化ｍｇｍｔプロモーターを含む腫瘍を治療する方法 |
| KR20260033048A (ko) | 2023-07-03 | 2026-03-10 | 네오이뮨텍, 인코퍼레이티드 | 이종이합체 fc 분자 및 이의 용도 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604114A (en) * | 1986-05-20 | 1997-02-18 | Dana-Farber Cancer Institute | Cis-acting repression sequences, cis-acting antirepression sequences, vectors, methods of preparation and use |
| EP0588914A1 (en) * | 1991-05-29 | 1994-03-30 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Eukaryotic expression vectors with regulation of rna processing |
| EP0759471A4 (en) * | 1994-05-10 | 1997-10-15 | Hisamitsu Pharmaceutical Co | RECOMBINANT VECTOR OF HUMAN IMMUNODEFICIENCY VIRUS AND METHOD FOR THE PRODUCTION THEREOF |
| WO1995032300A1 (en) * | 1994-05-23 | 1995-11-30 | University Of Medicine & Dentistry Of New Jersey | Selective biological destruction of tumor cells |
| US5693508A (en) * | 1994-11-08 | 1997-12-02 | Chang; Lung-Ji | Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats |
| JP3908274B2 (ja) * | 1995-03-09 | 2007-04-25 | ゲーエスエフ−フォルシュンクスツェントラム・フュア・ウムベルト・ウント・ゲズントハイト・ゲーエムベーハー | 遺伝子治療用の抗菌ペプチドをコードする治療用遺伝子を有するベクター |
| GB9510272D0 (en) | 1995-05-22 | 1995-07-19 | Isis Innovation | Retroviral vectors |
| WO1997048277A1 (en) * | 1996-06-20 | 1997-12-24 | The Salk Institute For Biological Studies | Modular assembly retroviral vectors and uses thereof |
-
1996
- 1996-10-17 GB GBGB9621680.9A patent/GB9621680D0/en active Pending
-
1997
- 1997-10-17 CZ CZ991372A patent/CZ137299A3/cs unknown
- 1997-10-17 NZ NZ334522A patent/NZ334522A/en not_active IP Right Cessation
- 1997-10-17 AT AT97909437T patent/ATE520783T1/de not_active IP Right Cessation
- 1997-10-17 HU HU0000442A patent/HUP0000442A3/hu unknown
- 1997-10-17 EP EP97909437A patent/EP0939827B1/en not_active Expired - Lifetime
- 1997-10-17 IL IL12856497A patent/IL128564A0/xx unknown
- 1997-10-17 CA CA002268271A patent/CA2268271A1/en not_active Abandoned
- 1997-10-17 GB GB9903117A patent/GB2331522B/en not_active Expired - Lifetime
- 1997-10-17 CN CNB971988838A patent/CN1195864C/zh not_active Expired - Lifetime
- 1997-10-17 AU AU47123/97A patent/AU737801B2/en not_active Expired
- 1997-10-17 US US09/284,011 patent/US6235522B1/en not_active Expired - Lifetime
- 1997-10-17 KR KR1019990703355A patent/KR20000049250A/ko not_active Ceased
- 1997-10-17 JP JP10519087A patent/JP2001502903A/ja not_active Ceased
- 1997-10-17 WO PCT/GB1997/002858 patent/WO1998017816A1/en not_active Ceased
- 1997-10-17 PL PL97332876A patent/PL332876A1/xx unknown
-
1999
- 1999-04-13 NO NO991742A patent/NO991742D0/no not_active Application Discontinuation
- 1999-04-14 BG BG103334A patent/BG103334A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1234075A (zh) | 1999-11-03 |
| ATE520783T1 (de) | 2011-09-15 |
| US6235522B1 (en) | 2001-05-22 |
| EP0939827B1 (en) | 2011-08-17 |
| HUP0000442A3 (en) | 2001-09-28 |
| CZ137299A3 (cs) | 1999-07-14 |
| BG103334A (en) | 2000-06-30 |
| AU737801B2 (en) | 2001-08-30 |
| HUP0000442A2 (hu) | 2000-06-28 |
| JP2001502903A (ja) | 2001-03-06 |
| NO991742L (no) | 1999-04-13 |
| CA2268271A1 (en) | 1998-04-30 |
| GB9621680D0 (en) | 1996-12-11 |
| HK1018481A1 (en) | 1999-12-24 |
| PL332876A1 (en) | 1999-10-25 |
| GB2331522B (en) | 2001-05-23 |
| KR20000049250A (ko) | 2000-07-25 |
| GB9903117D0 (en) | 1999-04-07 |
| NZ334522A (en) | 2001-11-30 |
| WO1998017816A1 (en) | 1998-04-30 |
| NO991742D0 (no) | 1999-04-13 |
| CN1195864C (zh) | 2005-04-06 |
| GB2331522A (en) | 1999-05-26 |
| AU4712397A (en) | 1998-05-15 |
| EP0939827A1 (en) | 1999-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2331522B (en) | Lentiviral vectors | |
| AU4712297A (en) | Retroviral vectors | |
| NZ500740A (en) | Recombinant lentivirus-based gene transfer vectors comprising 3 vectors from Equine Infectious Anemia Virus (EIAV) | |
| CA2104396A1 (en) | Viral particles having altered host range | |
| WO1998039463A3 (en) | Lentivirus based vector and vector system | |
| EP0759471A4 (en) | RECOMBINANT VECTOR OF HUMAN IMMUNODEFICIENCY VIRUS AND METHOD FOR THE PRODUCTION THEREOF | |
| CA2311641A1 (en) | Pseudo-type retroviral vectors with modifiable surface capsid proteins | |
| EP1262554A3 (en) | Defective packaging non-oncoviral vectors based on mpmv and hiv | |
| DE69534948D1 (de) | Retrovirale vektoren zur expression in embryonalen zellen | |
| PT975783E (pt) | "vectores retrovirais, processo para a sua producao e sua utilizacao para a transferencia de genes a celulas cd4-positivas" | |
| WO1994020621A3 (en) | Proteinaceous particles containing retroviral element | |
| NO983375D0 (no) | Retroviral vektor og anvendelse derav i genterapi | |
| GB2331989B (en) | Retroviral vectors | |
| DK631387A (da) | Virusvektor | |
| WO1995025806A3 (en) | Packaging-deficient lentiviruses | |
| WO2002086064A3 (en) | Inducible expression of transfected genes | |
| EP1433843A3 (en) | Novel xylanases, genes encoding them, and uses thereof |